Introduction: Endometriosis is a common gynecologic disorder defined as ectopic presence of endometrial tissue in extrauterine sites. Endometriosis is associated with infertility and risk of malignancy. Identification of genetic factors responsible for development and malignant transformation of endometriosis can improve therapeutic approaches. In this study, we investigated the association of AT-rich interaction domain 1A (ARID1A) and endothelial nitric oxide synthase (eNOS) polymorphisms with endometriosis and staging of the disease. Methods: A total of 100 women with laparoscopy-confirmed diagnosis of endometriosis were included and compared with 100 women without endometriosis as the control group. Genotypes of patients regarding Gln920Ter polymorphism of ARID1A gene and Glu298Asp polymorphism of eNOS gene were determined by polymerase chain reaction techniques on blood samples from the study population. The prevalence of each genotype in endometriosis patients was compared with healthy controls using the chi-square test. Results: Significantly higher prevalence of non-CC genotype for ARID1A Gln920Ter polymorphism and non-GG genotype for G894T polymorphism of the eNOS gene was detected in the endometriosis group. There was no significant relationship between these polymorphisms and staging of endometriosis. Discussion: Significant variation of prevalence of Gln920Ter polymorphism of the ARID1A gene and Glu298Asp polymorphism of the eNOS gene among the two groups can indicate a causative effect of these genetic alterations on the development of endometriosis.
Introduction
Ectopic presence of endometrial tissue in any site other than the uterus is called endometriosis and is responsible for a broad spectrum of clinical manifestations depending on the site of implantation of endometriotic progenitors. The most common location for endometriosis implants is within the pelvic cavity, but they can occur almost anywhere in the body. 1 Major etiologic factors and pathophysiologic mechanisms hypothesized for development of endometriosis are (1) metaplastic development from other epithelial tissues, (2) development from Mullerian remnants, and (3) implantation and growth of viable endometrial cells through retrograde menstruation. 2 Malignant transformation has been reported to be associated with endometriosis. Malignant transformation of an endometriotic lesion was first described in 1925 by Simpson, who reported the development of ovarian carcinoma from ovarian endometriosis. Seventy years later, molecular and genetic evidence were gathered, which associated molecular changes that occurred in endometriotic cells to those in malignant ovarian carcinomas. 2 Certain genetic alterations have been proposed to play a role in pathogenesis of endometriosis. Primary epidemiologic studies in the past decades have revealed familial clustering for endometriosis and high risk of the disorder in first-degree relatives of endometriosis patients, which suggests a potential genetic etiologic background for endometriosis. 3 Since then, studies have been conducted to determine genotypes that predispose individuals to endometriosis as well as those responsible for a greater risk of malignant transformation of endometriosis to ovarian epithelial cancers. Several genes and polymorphisms from various biomolecular classes have been introduced to play a role in predisposition to endometriosis and endometriosis-related carcinomas. Among these genes, the AT-rich interactive domain-containing 1A (ARID1A) gene has gained 1 attention because of a mutation polymorphism that downregulates its expression and thus leads to endometriotic lesions to ovarian carcinomas such as clear cell and endometrioid carcinomas. 4, 5 In 2012, Samartzis et al. 6 revealed that complete or partial loss of ARID1A expression is significantly more frequent in endometriomas as well as peritoneal and deep infiltrating endometriosis. In another study by Borrelli et al. in 2016 , the authors investigated partial loss of ARID1A expression in bowel deep infiltrating endometriosis, rectovaginal endometriosis, and endometriosis affecting the pelvic sentinel lymph node. The results revealed no significant variation of ARID1A loss of expression between the study groups and controls. 7 Endothelial nitric oxide synthase (eNOS), on the other hand, is one of the genes that undergoes functional alterations in pathogenesis of endometriosis 8 and is also reported to be associated with recurrent abortion and infertility. 9 ARID1A encodes a protein belonging to the mating-type switching/sucrose non-fermenting (SWI/SNF) family. This family of proteins plays a role in regulation of transcription by their helicase and ATPase activities. eNOS is the endothelial form of nitric oxide, which is responsible for regulating smooth muscle tone in the tunica muscularis layer of blood vessels. A polymorphism of the encoding gene known as Glu298Asp, in which glutamate is replaced with aspartate in the 298th position of amino acid chain, has been observed to have higher prevalence in endometriotic lesions and in patients with recurrent pregnancy loss and infertility. 8, 9 In this article, we investigated the prevalence of genotypes of Gln920Ter polymorphism of the ARID1A gene and Glu298Asp polymorphism of the eNOS gene in patients with endometriosis compared to controls.
Methods

Study population
In a case-control study conducted between December 2012 and May 2013, all patients who referred to the gynecology clinic due to recurrent pelvic pain, dysmenorrhea, and infertility were scheduled for laparoscopic resection of endometriosis were selected as the case group (we calculated sample size due to previous studies by biostatistics consultants with confidence interval of 95% by Cochran formula).
Transvaginal sonography was performed preferably, if possible to rule out other causes of abdominal pain in patients without typical presentations of endometriosis and visualize the endometriotic tissue. Those who presented with typical clinical signs and symptoms were scheduled for laparoscopy without sonography. Patients not responding to medical treatment or those preferring to undergo surgical excision of endometriotic lesions were candidate for laparoscopic resection of the endometriotic lesions and implants.
Inclusion criteria: Only patients with tissue confirmation were included in the study group and their tissue samples were examined for target genetic alterations.
Exclusion criteria were as follows:
1. History of medical disease such as cardiovascular disease, diabetes mellitus, hypertension, or hypercholesterolemia; 2. History of male factor infertility; 3. History of using medication for other indications.
The control groups comprised patients who were candidates for diagnostic and operative laparotomy and laparoscopy due to other gynecologic diseases without any laparoscopic finding suggestive of endometriosis. In this group, laparotomy was performed due to other indications such as myomectomy, ovarian cystectomy, and transabdominal hysterectomy. In addition, visualization of abdominal and pelvic cavities by an expert gynecologist did not reveal any sign of endometriosis, including typical "powder burn" lesions on the serosal peritoneum, dark brown/bluish nodules, flame-shaped hemorrhagic lesions, small cysts with surrounding fibrosis, vesicular, polypoid lesions, whitish plaques, areas of scarring or patches of yellow brown discoloration, or subovarian adhesions. Finally, histologic examination of the primary lesion (sample of myoma, cyst) confirmed non-endometriotic tissue in the control group. Exclusion criteria for this group were the same as the case group.
All patients were asked to sign an informed consent before being included in the study.
Study protocol
Before operation, blood samples were obtained from all patients by vein puncture. Blood specimens were transferred to the laboratory in EDTA-containing tubes in a temperature between 0°C and 4°C. DNA was extracted using the salting-out method and qualified using Thermo Fisher Nanodrop and finally stored at −70°C until further procedures were performed.
The operation was performed for all patients by the following standard protocol under general anesthesia. In the study group, whole excised endometriotic tissues were transferred to the pathology lab for confirmation of diagnosis and evaluation of the presence of possible malignant transformations. In the control group, in addition to performance of standard surgical procedure for their primary diagnosis, the pelvic area was thoroughly examined to confirm the absence of any endometriotic lesion. All patients were monitored in the hospital ward for 48 h after the operation. The preoperative, operative, and postoperative periods were nonproblematic for all patients, and no significant complication occurred.
DNA was extracted from blood samples obtained from control and case groups using commercial kit, Qamp (Qiagen, Inc., Germany). DNA quality checking was performed using a Thermo Fisher NanoDrop TM 2000c/2000 UV-Vis spectrophotometer. Amplification-refractory mutation system-polymerase chain reaction (PCR) technique was performed for genotyping of ARID1A and eNOS gene polymorphisms using specific primers. GAPDH primers were used as PCR internal control as well. About 10% of samples underwent sequencing double-check for evaluation of the procedure's precision.
All PCR amplifications were loaded on 2% agarose gel and stained with superior gel red as a Safe Bio Color for screening on transilluminator.
This study was approved and supervised by the ethics committee of the institutional review board for human medical research of Shiraz University of Medical Sciences.
Statistical analysis method
Expression of ARID1A and eNOS polymorphisms in blood samples from endometriosis was compared to that of the control groups using chi-square test by Statistical Product and Service Solutions (SPSS) 18, IBM Corp., Armonk, NY, USA. With a confidence interval of 95%, p-value <0.05 was considered significant.
Results
In this study, data were gathered from blood samples from 100 cases of endometriosis and 100 non-endometriotic patients as the control group. The study population consisted of 19-to 56-year-old women with a mean age of 30.6 years. The most common clinical presentation was dysmenorrhea, which was reported by 76 patients comprising 70.4% of the population. Figure 1 demonstrates the prevalence of common symptoms among endometriosis cases in this study. Figure 2 demonstrates prevalence of endometriosis stages (revised American society for reproductive medicine Descriptive statistical analysis was performed to measure the frequencies of each genotype of studied polymorphisms of eNOS and ARID1A genes within the case and control groups. Correlation of genotypes with tumor staging and clinical presentation was statistically evaluated using chi-square test. Prevalence of T allele of ARID1A polymorphism was significantly higher in the endometriosis group compared to healthy individuals (higher prevalence of heterozygous CT and homozygous TT). Regarding eNOS gene, the prevalence of GT heterozygous and TT homozygous genotypes was significantly higher indicating a higher prevalence of G allele. Table 1 describes the frequency of ARID1A and eNOS genotypes in the study groups.
We ran a statistical analysis for comparison of genotype profiles of patients with various presentations of the disease classified as (1) superficial/peritoneal endometriosis, (2) ovarian endometriosis, and (3) deep infiltrating/bowel endometriosis. The results showed that each group has significantly different genotypes from the control group (p-value <0.001) but a pairwise comparison of genotypes between groups did not show any statically significant difference in genotypes between various disease presentations (Table 2) .
We also compared the prevalence of stages of endometriotic lesions within any genotype of studied genes to find the correlation between patients' genotypes and staging of endometriosis. As Table 3 demonstrates, there was no significant correlation between genotypes and lesion staging.
Discussion
Endometriosis is a common gynecologic disorder affecting 5%-10% of all reproductive-age women. Several genes and molecular alterations have been studied for their role in development of endometriosis and its malignant transformation. 2 ARID1A and eNOS genes are among the genetic factors that have been recently studied for their mutation and alteration of functions in development and malignant transformation of endometriosis.
Recent genomic studies have found ARID1A to undergo mutations in ovarian clear cell carcinoma and endometrioid ovarian carcinoma. Mutations that silent the ARID1A gene or downregulate its expression result in impaired cell cycle control and cell proliferation. ARID1A is a human gene encoding BAF250a protein that regulates transcription of genes involved in cell cycle control by a DNAhelicase activity. ARID1A gene mutation and decreased production of its encoded protein has been documented in ovarian, endometrial, and uterine cancers, such as ovarian clear cell carcinomas and endometrioid carcinomas. Other types of human malignancies have also been recently associated with ARID1A mutations. These cancers include gastric, hepatocellular, breast, and pancreatic cancers and transitional cell carcinoma of the bladder. 10 In 2011, Wiegand et al. 4 from endometriotic lesions. They found that the most frequent genetic abnormalities observed in these tumors are inactivating mutations of the ARID1A gene. 11 Lowery et al. 12 reported the same findings; they investigated 212 cases of clear cell and endometrioid ovarian cancers. They reported loss of ARID1A expression in 45% of all cases, 41% in clear cell carcinomas, and 48% in endometrioid ovarian cancers. They also reported that there was no significant relationship between ARID1A expression and staging, grading, and survival of the studied carcinomas. However, Chandler et al. 13 reported that in addition to ARID1A mutation, coexisting activation of phosphoinositide 3-kinase catalytic subunit is required for clear cell carcinoma tumorigenesis. In a similar study in 2014, it was suggested that ARID1A mutation alone is not sufficient for tumorigenesis in endometrioid carcinoma. They reported that other genetic alterations such as phosphatase and tensin homolog inactivation are also required to induce malignant transformation. 14 In this study, we compared the prevalence of presentation of ARID1A between endometriosis patients and the control group. Similar to previous publications, our results indicated a higher prevalence of deactivating polymorphism of ARID1A gene, Gln920Ter polymorphism, in patients with endometriosis compared to the healthy population. Our findings regarding a lack of association between ARID1A genotype and staging and clinical presentation of patients with endometriosis also agreed with other studies.
eNOS gene is the other genetic factor that has been studied for its role in pathogenesis of endometriosis. Several polymorphisms of the eNOS gene have been linked to various disorders such as coronary artery disease, 15 diabetic nephropathy, 16 and diabetic retinopathy. 17 In another study, 786 T/C polymorphism of eNOS gene was proposed as a protective factor against atrial fibrillation. 18 Glu298Asp or G894 T polymorphism of the eNOS gene is one of the mutations that has been studied for its association with endometriosis 19 and other disorders such as end-stage renal disease, 20 Behçet's disease, 21 and hypertension. 22 In 2009, Kim et al. 19 investigated the prevalence of T allele of Glu298Asp polymorphism of eNOS gene in endometriosis for the first time. They reported a significantly higher prevalence of T allele of this polymorphism in 299 women with advanced-stage endometriosis compared to 459 controls from a Korean population. In 2011, Ozturk et al. 23 reported that the other polymorphism of eNOS gene, G894T, contributes to endometrial carcinoma. The results of this study confirmed the findings of Kim et al. 19 regarding the significantly higher prevalence of T allele of Glu298Asp polymorphism of eNOS gene in endometriosis patients, which can reveal a predisposing role of this mutation in development of endometriosis, although our data could not indicate any association between the staging of endometriotic lesions and the genotype of patients.
In this study, for the first time, we managed to identify genotypes of Gln920Ter polymorphism of ARID1A gene and Glu298Asp polymorphism of eNOS gene using blood sample PCR in 100 patients with surgically confirmed endometriosis and compared these measures with a control group consisting of 100 patients with surgically ruled-out diagnosis of endometriosis. The results of this study suggested a higher prevalence of TT homozygous and CT genotypes of Gln920Ter polymorphism of the ARID1A gene and TT homozygous and GT genotypes of Glu298Asp polymorphism of the eNOS gene in patients with endometriosis. This variation was significant with p-value <0.001. Measurements of genotype prevalence were also statistically analyzed regarding their association with clinical presentation and endometriosis staging. The results were not statistically significant for any correlation between genotypes of ARID1A and eNOS polymorphisms with clinical symptoms and staging of endometriosis. These results suggest strong association of ARID1A and eNOS polymorphisms with pathogenesis of endometriosis while they fail to associate them with characteristics and staging of endometriotic lesions. This association can be used to develop guidelines for detection and determination of prognosis in an asymptomatic family member of patients with endometriosis. However further investigation on a larger study population is required to increase validity of such an approach.
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